A study involving 1,225 patients with metastatic melanoma has identified a genetic trait linked to resistance against immune checkpoint inhibitors, a widely used form of immunotherapy.
2025
Immunotherapy Improves Overall Survival in Women With Genital Tract Melanoma
Overall survival (OS) in women with genital tract melanoma (GTM) is improved with immunotherapy, according to study findings published in Melanoma Research.
Balancing Efficacy and Safety: Toxicity Considerations With Melanoma Immunotherapy
Panelists discuss how treatment selection is personalized based on patient characteristics, with relatlimab-nivolumab or monotherapy preferred for frail patients with low disease burden, while ipilimumab-nivolumab might be considered for patients with brain metastases despite its higher toxicity.
Navigating Newer Treatment Regimens in Melanoma: Practical Approaches to Dosing and Adverse Event Management
Community adoption of newer immunotherapy combinations.